Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Details : LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharo...
Brand Name : LEV102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2023
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?